KWM
STLN

Kanen Wealth Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Kanen Wealth Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.53M Sell
2,777,858
-198,286
-7% -$608K 3.07% 9
2025
Q4 		$10.7M Buy
2,976,144
+1,134,043
+62% +$4.21M 3.25% 7
2025
Q3 		$6.42M Buy
+1,842,101
New +$6.31M 2.15% 11

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kanen Wealth Management's STLN Position: Q1 2026 in Review

Kanen Wealth Management reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 6.7% in Q1 2026, selling an estimated $608K and leaving 2,777,858 shares worth $8.53M. The position accounts for 3.07% of the portfolio, ranked #9.

Kanen Wealth Management first reported a position in STLN in Q3 2025 and has held it in 3 quarters since. The position peaked at $10.7M in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Kanen Wealth Management held 2,777,858 shares of Starling Oncology Institute, Inc. Common Stock worth $8.53M as of Q1 2026.
  • Kanen Wealth Management sold 198,286 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $608K.
  • Starling Oncology Institute, Inc. Common Stock made up 3.07% of Kanen Wealth Management's portfolio in Q1 2026, its #9 holding.
  • Kanen Wealth Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2025 and has held it in 3 quarters since.
  • Kanen Wealth Management's Starling Oncology Institute, Inc. Common Stock position peaked at $10.7M in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Kanen Wealth Management's 13F filing for Q1 2026, filed 18 May 2026.